Drug Information

Drug General Information
Drug ID
D0X5LR
Former ID
DNCL002230
Drug Name
BMN-673
Drug Type
Small molecular drug
Indication Psoriatic arthritis [ICD9: 696; ICD10:L40.5, M07] Phase 3 [524436], [543065]
Company
BioMarin Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C19H14F2N6O
InChI
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,25H,1H3,(H,26,28)/t15-,16-/m1/s1
InChIKey
IUEWAGVJRJORLA-HZPDHXFCSA-N
PubChem Compound ID
44819241
PubChem Substance ID
89447774, 136920298, 160647564, 163557122, 163621000, 164027304, 164045804, 164178297, 185989934, 189253964, 194154702, 198987937, 209523629, 209523631, 224764420, 228421645, 248916673, 251963003, 251972890, 252166525, 252444253, 252451198, 252552923
Target and Pathway
Target(s) Poly ADP ribose polymerase (PARP) Target Info Modulator [1572591]
References
Ref 524436ClinicalTrials.gov (NCT01945775) A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study). U.S. National Institutes of Health.
Ref 543065(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313).
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.